Patients with connective tissue diseases (CTD), like rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed CTD (MCTD), Sjögren’s syndrome (SS), and inflammatory myopathies (IIM) are at a varying degree at risk of developing interstitial lung disease (ILD); but once ILD is present morbidity and mortality are high.
ILD associated with connective tissue diseases (CTD-ILD) share common biomarkers, suggesting common pathophysiological pathways. Disease behaviour is unpredictable, resulting in poor prognosis.
The aims of the session are to identify prognostic markers in order to predict disease clinical course and guide treatment of connective tissue disease-associated interstitial lung diseases (CTD-ILD).
Several serum biomarkers have been investigated as helpful for diagnosis and prognosis of ILD, although disease specific biomarkers are lacking, and large longitudinal studies are needed to contribute to patient’s management.
For the last two years, we have witnessed the emergence of new treatment options in the field of CTD-ILD: some studies on biological treatments (Rituximab, Tocilizumab) have yielded interesting results that suggest an effect of these drugs on the lungs of patients’ subpopulation. Furthermore, the results of the SENSCIS and INBUILD trials are a major breakthrough, paving the way for the use of antifibrotics in CTD-ILD. However, difficult challenges remain: is it possible to predict fibrosis and progression? How could we identify patients at risk?
The audience will gain knowledge on the diagnostic/prognostic challenges and novel therapeutic advances in CTD-ILD.
- Introduction from the chairs – 2 minutes
- Predicting outcomes in CTD-ILD – 21 minutes
- The use of antifibrotics and immune modulators; the pulmonologist and rheumatologist in the same room? – 21 minutes
E. Renzoni, O. Distler, Switzerland
- Q&A – 15 minutes
- Wrap-up and closing – 1 minute
- Lectured-based presentation on relevant diagnostic, prognostic and therapeutic aspects of CTD-ILD.
- Outcomes in CTD-ILD
- Novel treatment options for CTD-ILD
Following the webinar, participants will be able to:
- Undertake correct assessment steps in diagnosis, prognosis of CTD-ILD
- Accordingly recommend an appropriate novel treatment modality in the management of CTD-ILD patients
This webinar is accredited by the European Board for Accreditation in Pneumology (EBAP) and awards 1 CME credit per 1-hour attendance. The CME credit will be granted upon attendance during the live webinar only (attendance of at least 60 minutes is required).
What is a webinar?
The webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting.
This webinar comprises a 40-minute lecture followed by a 20-minute question-and-answer session. During the webinar you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
More information will be communicated in due course.
- Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact firstname.lastname@example.org.
- Check Central European Summer Time.
- To achieve the best quality, we recommend stopping all other programmes and avoiding downloading anything from the internet during your connection to the lecture.
- Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.
Diseases / methods
- Interstitial lung diseases